Erratum: Current and Emerging Biomarkers in Metastatic Colorectal Cancer
BC Cancer, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(6), 404; https://doi.org/10.3747/co.26.6145
Submission received: 8 September 2019
/
Revised: 5 October 2019
/
Accepted: 4 November 2019
/
Published: 1 December 2019
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
In the initially published manuscript, the article stated (about the BEACON clinical trial) that “Interestingly, the triplet did not appear more active than the combination of encorafenib and binimetinib (mos: 9.0 months vs. 8.4 months; HR: 0.79; 95% CI: 0.59 to 1.06).” [...]
Share and Cite
MDPI and ACS Style
Lee, M.K.C.; Loree, J.M. Erratum: Current and Emerging Biomarkers in Metastatic Colorectal Cancer. Curr. Oncol. 2019, 26, 404. https://doi.org/10.3747/co.26.6145
AMA Style
Lee MKC, Loree JM. Erratum: Current and Emerging Biomarkers in Metastatic Colorectal Cancer. Current Oncology. 2019; 26(6):404. https://doi.org/10.3747/co.26.6145
Chicago/Turabian StyleLee, M. K. C., and J. M. Loree. 2019. "Erratum: Current and Emerging Biomarkers in Metastatic Colorectal Cancer" Current Oncology 26, no. 6: 404. https://doi.org/10.3747/co.26.6145
